Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Apalutamide - Janssen Research and Development

Drug Profile

Apalutamide - Janssen Research and Development

Alternative Names: ARN-509; ERLEADA; Erleada; ERLYAND; JNJ-56021927; JNJ-927

Latest Information Update: 09 May 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Aragon Pharmaceuticals; University of California
  • Developer Aragon Pharmaceuticals; Case Comprehensive Cancer Center; Dana-Farber Cancer Institute; Instituto do Cancer do Estado de Sao Paulo; Janssen Research & Development; M. D. Anderson Cancer Center; Singapore General Hospital
  • Class Antiandrogens; Antineoplastics; Aza compounds; Benzamides; Pyridines; Small molecules; Spiro compounds; Sulfhydryl compounds; Thiohydantoins
  • Mechanism of Action Androgen receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Prostate cancer
  • Phase II Salivary gland cancer

Most Recent Events

  • 03 May 2024 Updated efficacy and adverse events data from a phase II trial in Prostate cancer released by Johnson & Johnson
  • 13 Feb 2024 Aragon Pharmaceuticals completes a phase Ib trial for Prostate cancer (Hormone refractory, Metastatic disease, Combination therapy, Second-line therapy or greater) in USA (NCT01792687)
  • 25 Jan 2024 Updated efficacy and adverse events data from a phase II trial in prostate cancer presented at the 2024 Genitourinary Cancers Symposium (ASCO-GCS-2024)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top